Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Objective: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). Methods: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pranay Sinha, Anahita Mostaghim, Catherine G. Bielick, Angela McLaughlin, Davidson H. Hamer, Lee M. Wetzler, Nahid Bhadelia, Maura A. Fagan, Benjamin P. Linas, Sabrina A. Assoumou, Michael H. Ieong, Nina H. Lin, Ellen R. Cooper, Karrine D. Brade, Laura F. White, Tamar F. Barlam, Manish Sagar
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020-10-01
Colecção:International Journal of Infectious Diseases
Assuntos:
COVID-19
Tocilizumab
Sarilumab
Interleukin-6 inhibitors
Cytokine release syndrome
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1201971220305683
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados